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ABSTRACT 
Six well investigated patients of primary hyperphagic obesity with hypochondrical disorder 
were sequentially treated with psychoeducational methods alone and psychoeducational methods 
with naltrexone hydrochloride 50 mg daily orally for six weekseach. RMANOVA revealed no statically 
significant (p>0.05) decrease in body mass index suggesting that psychoeducational methods with 
naltrexone were as ineffective in reducing obesity as psychoeducational methods alone. The 
limitations of the study and implications for future research are discussed. 
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There is ample evidence regarding the 
role of endorphinergic mechanisms in the 
modulation of eating behaviour (Cooper & 
Sanger, 1984; Reid, 1985; Morley, 1987; Cooper 
et al.,1988; Levine & Billington, 1989; Bakshi & 
Kelley, 1993a & 1993b; Cooper & Kirkhan, 1993; 
Halmi, 1995). However, the use of opioid 
receptor antagonists in eating disorders including 
obesity has given conflicting results (Sullivan, 
1980; Cooper& Sanger, 1984; Cohen et al.,1985; 
Fantino et al.,1986; Jonas & Gold, 1986,1988; 
Mitchell et al., 1986,1989; Cooper et al.,1988; 
Levine & Billington. 1989; Bertino et al.,1991; 
Benjamin & Buot-Smith 1993; Clearly et 
al.,1996). Heterogeneity of the various diagnostic 
entities may be an important reason for such 
conflicting findings and it may be more rewarding 
to conduct studies on small subgroups of well 
delineated eating disorders (Fard & Bankum, 
1996). We came across a family in which six 
members had hypochondriacal disordei with well 
investigated primary hyperphagic obesity 
thereby providing us with an opportunity to 
evaluate the role of naltrexone in weight-
reduction in such patients. 
MATERIAL & METHOD 
The population of the study consisted of 
six siblings (male 2, female 4, age range 23-41 
years) from one family. All the six patients were 
obese with Body Mass Index (BMI)>35 Kg/mt
2 
at the time of recruitment in the study. They 
also had a persistent belief in the presence of 
cardiac disorder ("heart-attack") despite normal 
clinical examination, negative investigations & 
reassurance from cardiologists and physicians, 
thus satisfying the criteria for hypochondriacal 
disorder according to ICD-10 (World Health 
Organization, 1992). None of the patients had a 
history of anorexia or bulimia nervosa. All of 
these patients had been evaluated intensively 
in India and abroad for risk-factors for heart 
disease and were found to have none except 
obesity, occasional drinking, smoking, 
hypertriglyceridemia (secondary to obesity) in all 
the six siblings and use of oral contraceptives in 
the four female sibs. The patients had normal 
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EKGs, Hotter monitoring, treadmill test, Doppler 
scan, ejection fraction, radionucleotide, cardiac 
scan, creatinine clearance test, glucose 
tolerance test, lipid. profHe (except increased 
triglycerides secondary to obesity) thyroid 
function test, dexamethasone suppression test 
but had evidence of increased fat mass on total 
body electrical conductivity and computerised 
split conduction adipometry during the past one 
year. The patients were included in a 12 week 
study protocol after informed consent. 
Throughout this period a trained dietician made 
twice a week domicilary visits for dietary 
guidance, excercises, counselling, cognitive cue 
feedback therapy (recording by family members 
of the mood state and enviornmental factors 
preceding the desire to eat so that they may be 
apprised the relationship between the former & 
latter) and cognitive visual profile feedback 
(showing the patients their computer generated 
pictures at various projected body weights so as 
to enhance their motivation to reduce). The 
patients were kept drug free during the first six 
weeks but were given naltrexone hydrochloride 
50 mg orally daily during the later six weeks of 
the study. Throughout the study period, the 
patients were advised to reduce their total calorie 
intake but no restrictions were made on 
frequency or type of food taken. Body Mass 
Indices (weight in Kg/height in meters
2) of the 
patients calculated at the beginning of the study, 
after 6 weeks after 12 weeks are shown in table. 
RESULTS 
The mean body mass index of the group 
at three time points (baseline, 6 weeks and 12 
weeks) was not statistically significantly different 
from each other on Repeated Measures Analysis 
of Variance (RMANOVA) suggesting the 
naltrexone with psychoeducational measures 
(dietary guidance & counselling + cognitive cue 
feedback therapy + cognitive visual profile 
feedback therapy) was as ineffective in reducing 
body mass index of our patients as 
psychoeducational measures alone. 
TABLE 
BODY MASS INDEX AT BEGINNING, SIX WEEKS ANO 
TWELVE WEEKS OF TRIAL 
Patient Body Mass Index (Kg/Meter
2) 
no. at beginning 
1 3647 
2 38.40 
3 3943 
4 40.82 
5 3655 
6 37 33 
after six weeks 
36 45 
38 42 
39.44 
40 77 
36 62 
37.36 
after twelve weeks 
36 44 
38 40 
39.45 
40.81 
36.61 
37 34 
vtean±S.D.38.1833±1.7150 38.1767±1.7011 38.1750±1.7191 
Statistical 
Significance F=0.164 
(RMANOVA) 
p>0 05 
DISCUSSION 
Because of differences in methodology 
and patient sample, our findings cannot be 
compared with other studies which evaluated the 
role of naltrexone in obesity (Cohen et at., 1985; 
Fantino et al.,1986; Bertino et al.,1991; Benjamin 
& Buot-Smith,1993). The findings of inefficacy 
of naltrexone in our study should be interpreted 
in the light of the limitations of the study viz small 
number of patients (n=6), open nature of trial, 
absence of placebo-control and absence of 
quantitative adipometric evaluation after 6 & 12 
weeks of trial. The patients had comorbid 
hypochondriacal disorder and we have not been 
able to find any literature regarding 
endorphinergic mechanisms in their disorder. 
This raises a question which can not answer at 
the moment "Would our patients have responded 
differently to naltrexone if they did not have 
comorbid hypochondriacal disorder?". In 
addition, we have adopted a free food choice 
preocedure for the patients which did not take 
into consideration certain important variables like 
meal size, meal duration, meal frequency, inter-
meal interval, preferential ingestion of 
micronutrients, change of taste, etc., which may 
be selectively affected by endorphinergic 
mechanisms (Bertino et al.,1991; Parker & 
Rennie, 1992; Clearly et al., 1996, Gosnell & 
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Levine, 1996). Endophinergic mechanisms 
modulated appetite probably by their action on 
mesolimbic (ventral tegmental-nucleus 
accumbens) dopaminergic system leading to 
altered reward-value and motivation-incentive 
towards food (Cooper & Sanger, 1984; Bakshi & 
Kelley, 1993a, 1993b; Badiani et al .1995; 
Berridge, 1996; Kelley et al.,1996; Zhang & 
Kelley, 1997). Psychoeducational techniques 
(e.g., cognitive visual profile feedback therapy) 
also can modify the reward-value and motivation 
of an individual towards food, hence the 
simultaneous use of such techniques in this study 
may act as a confounding variable, there is need 
for a placebo controlled double blind study with 
crossover design to evaluate the role of 
naltrexone in a large population of well 
investigated primary hyperphagic obese patients 
without any comorbidity. If such a study replicates 
the findings of the present study, we should 
seriously consider the alternative possibility 
proposed by Walsh & Devlin (1998) that 
endorphinergic abnormalities may be the 
consequence rather than the cause of obesity. 
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